It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder.

Managing agitation in nursing home patients with Alzheimer’s disease and related dementias could be improved by augmenting Minimum Data Set data with information from electronic medical records.

This article will explore the latest research findings on medications linked to dementia, examining how different types of drugs may impact brain health and cognitive function.

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a study led by the ...

Axsome Therapeutics AXSM announced that it has received formal feedback from the FDA on its plans to seek approval for AXS-05 as a treatment for agitation in Alzheimer’s disease (AD) patients.

The article emphasizes the emotional and social challenges faced by those with dementia and stresses meaningful engagement ...